gptkbp:instanceOf
|
gptkb:biotechnology
|
gptkbp:CEO
|
gptkb:Paul_Hudson
|
gptkbp:country
|
gptkb:France
|
gptkbp:founded
|
1973
|
gptkbp:foundedBy
|
gptkb:Elf_Aquitaine
|
gptkbp:headquartersLocation
|
gptkb:Paris,_France
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi Group
|
gptkbp:industry
|
Pharmaceuticals
|
gptkbp:language
|
gptkb:French
English
|
gptkbp:legalForm
|
Société Anonyme
|
gptkbp:listedOn
|
gptkb:Euro_Stoxx_50
gptkb:CAC_40
NYSE (ADR: SNY)
|
gptkbp:marketCap
|
~€110 billion (2024)
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
gptkbp:netIncome
|
€6.72 billion (2023)
|
gptkbp:notableAcquisition
|
gptkb:Synthorx_(2019)
gptkb:Genzyme_(2011)
Bioverativ (2018)
Principia Biopharma (2020)
Translate Bio (2021)
Kadmon Holdings (2021)
|
gptkbp:numberOfEmployees
|
~91,000
|
gptkbp:parentCompany
|
nan
|
gptkbp:predecessor
|
gptkb:Sanofi-Synthélabo
gptkb:Aventis
|
gptkbp:product
|
gptkb:Myozyme
gptkb:Stilnox
gptkb:Allegra
gptkb:Aprovel
gptkb:Enterogermina
gptkb:Vaxigrip
gptkb:Maalox
gptkb:Amaryl
gptkb:Aubagio
gptkb:Clexane
gptkb:Dupixent
gptkb:Kevzara
gptkb:Lantus
gptkb:Menactra
gptkb:Pentacel
gptkb:Plavix
gptkb:Praluent
gptkb:Toujeo
Flagyl
Buscopan
Doliprane
Essentiale
Magne B6
No-Spa
Clamoxyl
Depakine
Fervex
Hexyon
Lasilactone
Polio vaccines
Rabies vaccines
Solian
Telfast
Yellow fever vaccines
|
gptkbp:products
|
Consumer healthcare products
Vaccines
Pharmaceutical drugs
|
gptkbp:researchInterest
|
Oncology
Vaccines
Immunology
Diabetes
Consumer healthcare
Multiple sclerosis
Rare diseases
Cardiovascular diseases
|
gptkbp:revenue
|
€43.07 billion (2023)
|
gptkbp:servesArea
|
Worldwide
|
gptkbp:stockExchange
|
gptkb:Euronext_Paris
|
gptkbp:stockSymbol
|
SAN
|
gptkbp:subsidiary
|
gptkb:Sanofi_Pasteur
gptkb:Genzyme
gptkb:Chattem
|
gptkbp:website
|
https://www.sanofi.com/
|
gptkbp:bfsParent
|
gptkb:Sanofi_Egypt
|
gptkbp:bfsLayer
|
7
|